NIH Licenses Gene-Editing Breakthrough to Cure Rare ROSAH Syndrome Vision Loss
Published Date: 3/20/2026
Notice
Summary
The National Institutes of Health is offering a cool new gene-editing invention that can fix a rare genetic disease called ROSAH syndrome, which causes vision loss and other problems. Companies can license this technology to develop treatments that might restore vision and improve lives. Interested parties should act soon and be ready to sign a confidentiality agreement to get all the details.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Potential Vision-Restoring Therapy For ROSAH
Researchers report a gene-editing method that precisely repairs the ALPK1 p.Thr237Met mutation in patient-derived cells with high accuracy and no side effects in lab tests, and the therapy could be delivered to the eye or salivary glands or via corrected patient cells returned to the patient. This technology could, if developed and commercialized, offer personalized treatment to restore vision and improve quality of life for people with ROSAH syndrome.
Government Gene-Editing Available for Licensing
The National Institute of Allergy and Infectious Diseases (NIAID) is offering a gene-editing technology that fixes the ALPK1 p.Thr237Met mutation (causing ROSAH syndrome) for licensing to commercial developers under 35 U.S.C. 209 and 37 CFR part 404. Companies interested in commercializing the invention should reference HHS Reference No. E-044-2024-0 when contacting the licensing office.
Agency Seeking Research Collaborators
NIAID is seeking statements of capability or interest from parties for collaborative research to further develop, evaluate, or commercialize this technology, with specific interest in human clinical trials. Parties that want to collaborate should contact David Yang at 240-695-6406 or [email protected].
Patent Filings Extend Market Coverage
Intellectual property associated with this invention includes Provisional Patent Application No. 63/733,836 filed December 13, 2024, and PCT Patent Application No. PCT/US2025/059432 filed December 12, 2025; foreign patent applications have been filed on selected inventions and may be available for licensing to extend market coverage. Reference: HHS Reference No. E-044-2024-0.
Technology Is At Pre-Clinical Stage
The notice states the invention's development stage as "Pre-Clinical," indicating it has laboratory results but has not yet entered human clinical trials. NIAID specifically notes interest in collaborators for human clinical trials to advance development.
Confidentiality Agreement Needed For Details
To receive copies of unpublished information about the invention, interested parties must sign a Confidential Disclosure Agreement (CDA) before NIAID will share full details. Contact David Yang at 240-695-6406 or [email protected] to request information and the CDA.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06283 — Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration
The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!
2026-05957 — Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding several closed virtual meetings in April 2026 to review and decide on important research grant applications. These meetings affect scientists seeking funding in areas like neuroscience, cancer, and liver disease. No public access is allowed to protect private info and trade secrets, and these reviews help decide where millions in research money will go.
2026-05672 — National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings
The National Institute on Deafness and Other Communication Disorders is holding two closed meetings in late April and early May 2026 to review grant applications and evaluate researchers’ qualifications. These meetings affect scientists seeking funding and help ensure top-notch research gets supported. No public access means privacy is protected, and the process keeps the money flowing to the best projects on time.
2026-05738 — Submission for OMB Review; 30-Day Comment Request; National Institutes of Health (NIH) Loan Repayment Programs, (Office of the Director)
The NIH is asking for a 30-day public comment on extending its Loan Repayment Programs that help doctors and scientists pay off their student loans while they do important health research. This extension keeps the program running smoothly with no big changes, and comments are due by April 23, 2026. If you’re a researcher with student loans, this program could save you money while you help improve health!
2026-05673 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 17, 2026, to review and evaluate important grant applications in health and science fields. These meetings protect private info and trade secrets while deciding who gets funding. Researchers and organizations applying for grants should note these dates as they impact funding decisions but don’t involve public attendance or extra costs.
2026-05238 — Submission for OMB Review; 30-Day Comment Request Hazardous Waste Worker Training-42 CFR Part 65, National Institute of Environmental Health Sciences (NIEHS)
The National Institute of Environmental Health Sciences (NIEHS) is asking for public feedback on their plan to collect info from groups that train hazardous waste workers. This helps make sure the training programs are effective and safe. If you’re involved in hazardous waste training, your input matters before the review deadline on March 18, 2026, and there’s no new cost for participants.
Previous / Next Documents
Previous: 2026-05526 — Center for Scientific Review; Notice of Closed Meetings
The Center for Scientific Review is holding several closed virtual meetings on April 16, 2026, to review and evaluate grant applications and contract proposals. These meetings protect private info and trade secrets, so the public can’t attend. Researchers and organizations applying for funding should note these important review dates as they impact which projects get supported.
Next: 2026-05528 — Agency Information Collection Activities; Comment Request; State Workforce Program Certification
The Department of Education wants your thoughts on a new form for State Workforce Programs to certify their info. This helps make sure the government collects only what’s needed without extra hassle. If you’re involved with these programs, you can comment by May 19, 2026—no cost changes, just smoother paperwork!
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in